# Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

> **NCT02476617** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 25 (actual)

## Conditions studied

- Chronic Hepatitis C
- Hepatitis C (HCV)
- Hepatitis C Genotype 1a

## Interventions

- **DRUG:** ombitasvir/paritaprevir/ritonavir
- **DRUG:** dasabuvir
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT02476617
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2016-08
- **Final completion:** 2016-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02476617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02476617, "Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02476617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*